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Abstract
Background and aims: Advances in the medical management of inflammatory bowel disease (IBD)
have altered treatment targets. Endoscopic mucosal healing is associated with better outcomes in
IBD, though less is known about the significance of achieving histological remission. Our aim was to
perform a systematic review to investigate whether histological or ‘complete’ remission constitutes
a further therapeutic target in IBD.
Methods: A bibliographic search was performed on the 1st of October 2013 and subsequently on
the 1st of March 2014 of online databases (OVID SP MEDLINE, OVID EMBASE, National Pubmed
Central Medline, Cochrane Library, ISI, conference abstracts), using MeSH terms and key words:
(“inflammatory bowel diseases” OR “crohn disease” OR “ulcerative colitis” OR “colitis”) AND
(“mucosal healing” OR “histological healing” OR “pathological healing” OR “histological scoring”
OR “pathological scoring”).
Results: The search returned 2951 articles. 120 articles were cited in the final analysis. There is no
validated definition of histological remission in IBD. There are 22 different histological scoring
systems for IBD, none of which are fully validated. Microscopic inflammation persists in 16–100% of
cases of endoscopically quiescent disease. There is evidence that histological remissionmay predict
risk of complications in ulcerative colitis beyond endoscopic mucosal healing, though data are
scarce in Crohn's disease.
Conclusions: Histological remission in IBD represents a target distinct from endoscopic mucosal
healing, not yet routinely sought in clinical trials or practice. There remains a need for a standardized
and validated histological scoring systemand to confirm the prognostic value of histological remission
as a treatment target in IBD.16 586 4800x2296; fax: +1 416 586 8481.
.on.ca (R.H. Riddell).
014.08.011
r B.V. on behalf of European Crohn's and Colitis Organisation. This is an open access article under the
ommons.org/licenses/by-nc-nd/4.0/).
1583Histological remission in IBD© 2014 Published by Elsevier B.V. on behalf of European Crohn's and Colitis Organisation. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1583
2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1583
3. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1584
4. What is histological healing in IBD? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1584
4.1. Histopathology in IBD and mechanisms of mucosal healing . . . . . . . . . . . . . . . . . . . . . . . . . . . 1584
4.2. Defining histological remission in IBD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1584
5. Appraisal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1584
6. How to measure histological remission? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1585
6.1. Practical aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1585
6.2. Histological scoring systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1585
6.2.1. Appraisal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1585
7. Current trials and evidence for histological remission as an endpoint . . . . . . . . . . . . . . . . . . . . . . . . 1585
7.1. Histological healing versus endoscopic mucosal healing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1585
7.2. Prognostic value of histology in IBD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1587
7.3. Therapeutic trials and histological remission . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1587
7.3.1. Appraisal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1589
8. Limitations of histological assessment in IBD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1589
9. Summary and future directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1589
Conflict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1593
Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1593
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15931. Introduction
Therapeutic advances in medical management have altered
treatment targets for inflammatory bowel disease (IBD).1,2
Consensus recommendations for clinical practice and trial
endpoints support striving not only for resolution of symptoms,
but also for endoscopic mucosal healing.2–9 This has been
defined as resolution of visible inflammation and ulceration at
endoscopy, variably Mayo 0 or 1.2 This endoscopic endpoint is
associated with prolonged clinical remission, lower rates of
hospitalization and lower rates of colectomy.10–16 The question is
whether biopsies, taken at the time of endoscopy for evaluation
of microscopic mucosal healing, add sufficient therapeutic
value to constitute a further target: ‘complete’mucosal healing,
or ‘complete remission’.
Endoscopic mucosal healing does not necessarily reflect
quiescent microscopic disease.17–19 Persistent microscopic
inflammation, both acute and chronic, in patients with
ulcerative colitis (UC) has been associated with increased
relapse rates, hospitalization, colectomy and risk of colorectal
neoplasia.18,20–27 Despite the intuitive importance of micro-
scopic activity as the harbinger of visible disease and clinical
relapse, histological remission has yet to be recommended
as a therapeutic endpoint for clinical trials or practice in
IBD.1,2,28 Yet it is worth reflecting that 50 years ago, Sidney
Truelove described clinical, endoscopic and histological end-
points in trials of UC,29 and that it was histopathology that
identified the difference in efficacy between sulfapyridineand 5-aminosalicylic acid to define the active moiety of
sulfasalazine.30 A histological endpoint is likely to be more
relevant in UC than Crohn's disease (CD), because the diffuse
mucosal inflammation in UC is less subject to biopsy bias
than the patchy transmural inflammation of CD, although the
transmural component is invariable in areas with severe
mucosal disease.
This systematic review was conducted as part of an
initiative by the International Organisation of Inflammatory
Bowel Disease (IOIBD) to analyze the available evidence for
treatment targets in IBD, including histopathology.
2. Methods
A bibliographic search was performed on the 1st of October
2013 of the online databases: OVID SP MEDLINE (1946 to
present), OVID EMBASE (1980 to present), National Library of
Medicine's Pubmed Central Medline (1950 to present), the
Cochrane Library, the ISI Web of Science and conference
abstracts (Digestive Diseases Week and European Crohn's
Colitis Organisation Congress) (2005 to present). An updated
search was performed on the 1st of March 2014. Each
database was searched for Medical Library Subject heading
(MeSH) terms and key words: (“inflammatory bowel diseases”
OR “crohn disease” OR “ulcerative colitis” OR “colitis”) AND
(“mucosal healing” OR “histological healing”OR “pathological
healing” OR “histological scoring” OR “pathological scoring”).
Randomized studies, case–control studies, cohort studies and
1584 R.V. Bryant et al.review articleswere included. Case reports, non-English articles,
and studies pertaining to non-human subjects were excluded.
Citations, abstracts and retrieved full-text publications of all
eligible articles were reviewed and screened for relevance by
two authors (RVB and SW).3. Results
A total of 2951 articles were returned using the initial search,
and after application of exclusion criteria, 1265 articles were
screened for relevance and a recursive search of articles
referenced in the bibliographies of retrieved articles was
performed. 120 articles were included in the final analysis;
22 review articles, 3 Cochrane review articles, 92 original re-
search papers, and 3 conference abstracts. Histological scoring
systems were extracted for analysis; a total of 18 different scor-
ing systems were identified. Two authors independently judged
study eligibility with full agreement.4. What is histological healing in IBD?
4.1. Histopathology in IBD and mechanisms of
mucosal healing
Histological changes in UC are characterized by evidence of
prior crypt destruction (crypt architectural distortion, atrophy
in which crypts may not reach the muscularis mucosae, and
Paneth cell metaplasia) and a mucosal inflammatory infiltrate
that is typically diffuse. Inflammatory changes are character-
istically continuous (being maximal distally), though patchy
inflammation can occur, especially after treatment. Active
disease is reflected by neutrophils within the crypt epithelium
and crypt lumen (cryptitis and crypt abscesses), and ultimate-
ly by erosions and ulcers. Quiescent disease is characterized
by the lack ofmucosal neutrophils, although degrees of chronic
inflammation may remain.
Severe chronic inflammation in the lamina propria in-
variably includes basal plasmacytosis. This means a plasma
cell infiltrate in the lower third of the lamina propria im-
mediately above the muscularis mucosae and between crypt
bases.31–33 Basal plasmacytosis can be seen in all forms of
longstanding colitis, so has a high predictive value for a diag-
nosis of IBD, particularly in differentiating it from infective
colitis.34,35 Care has to be taken in adults not to include bio-
psies from the region of the ileocaecal valve because, like ileal
biopsies, plasma cells can normally be seen in a basal location.
In resected specimens, CD is characterized by focal, often
discontinuous, chronic active mucosal inflammation that
includes transmural lymphoid hyperplasia in the most severe
areas of mucosal inflammation. Architectural distortion
may be similar to UC, but when present, granulomas unrelat-
ed to crypt injury are then virtually pathognomonic of CD.
Granulomatous inflammation may be associated with a higher
rate of clinical relapse and surgery in patients with CD.32,33,36
Recurrent epithelial damage with consequent disruption
of intestinal barrier function is a key feature of IBD.16,37
Mucosal healing, contingent on epithelial restitution and repair,
is associated with suppression of inflammation and enhanced
barrier function.16 This is a complex process controlled by
regulatory growth factors, peptides and cytokines, dependenton the balance of proliferation, migration and functional dif-
ferentiation of intestinal epithelial cells at the injured edge.16
Pivotal molecules include growth factors (TGF α/β, epidermal
growth factor, cytokines IL-6 and Il-22, and bacterial lipopoly-
saccharide through Toll-like receptors) all of which induce in-
tracellular signaling cascades to activate NF-kB and STAT-3
pathways in epithelial cells.16,37,38
4.2. Defining histological remission in IBD
No standard definition of histological remission exists, either
for UC or CD.2,39–44 Unfortunately, the terms histological
‘healing’ and ‘remission’ appear interchangeable, although
they are not necessarily synonymous.17,40,45,46 The term
‘mucosal healing’ is unclear with regard to cells that are,
or are no longer, present or change their number or proportion,
and needs to be separated from endoscopic healing. Further-
more, the emerging concept of ‘deep remission’ in CD, defined
as ‘clinical remission’ (a CDAIb150merits the inverted commas)
and endoscopic healing without ulceration, does not include
histopathology,47,48 which sheds light on all other cellular ele-
ments short of overt ulceration.
As a consequence of multiple histological scoring systems
for UC, definitions of pathological remission range from re-
sidual inflammation with persistent architectural distortion,
to normalization of the colonic mucosa,18,22,49–56 although all
generally accept it to mean at least a lack of active mucosal
inflammation (neutrophils). The ‘Global Histologic Disease
Activity Score’ offers a tool for measurable histological im-
provement in CD, but is not validated.57 In an expert position
statement on endpoints for clinical trials in CD in 2009, there
was no consideration of histological endpoints or remission,
neither was there a pathologist on the study.1
5. Appraisal
Despite 60 years of clinical trials in IBD, no definition of his-
tological remission has been validated. It has been stated that
validation of any definition will require a process of regression
analysis of specific histological features, alongside assessment
of interobserver and intraobserver reliability using multiple,
credible central readers.44 However, central reading means
that the system is not robust enough to be generalizable and
is therefore not usable by practicing pathologists. While cen-
tral reading may be a good tool to validate a system initially,
ultimately the system needs to be usable by all interested
practicing pathologists. Thereafter, histological remission may
be incorporated as an endpoint in clinical trials to assess its role
in predicting disease-related complications and outcomes, and
ultimately into general clinical practice.
We propose that the histological treatment target for UC
or CD is to:
a) induce absence of neutrophils (both in the crypts and lamina
propria);
b) induce the absence of basal plasma cells and ideally reduce
lamina propria plasma cells to normal; and
c) reduce lamina propria eosinophils to normal.
The target will be easier to detect (and conceivably easier
to achieve) in UC rather than CD, but the histopathological
1585Histological remission in IBDprinciple is the same. Incorporation of histopathological exam-
ination of biopsies in establishing remission in IBD goes beyond
‘deep remission’ and may be better termed ‘complete remis-
sion’, implying concordance between clinical, endoscopic and
histological remission.
6. How to measure histological remission?
6.1. Practical aspects
The accuracy of diagnosing colitis not surprisingly increases
from 66% to 92% when segmental biopsies throughout the
colon are taken, rather than two biopsies.58 Multiple sections
from each sample stained for hematoxylin and eosin increase
the yield.32 The same seems likely for assessing disease ac-
tivity in IBD, and correlation of pre- and post-treatment disease
activity stratified to location (e.g. rectum, sigmoid colon, etc.)
will be critical for accurate comparison. Rectal biopsies are
also invaluable as UC sparing the rectummay not exist, although
in patients with primary sclerosing cholangitis, colitis may be
predominantly right-sided.59 In clinical trials, the operating char-
acteristics of histopathological scores will vary depending on
the number, quality, and distribution of the samples taken.44
For any scoring system that requires evaluation of basal
plasma cells, the basal part of the mucosa needs to be iden-
tified. This can only occur in biopsies that have sections cut to
allow the surface and the deep part of the biopsy to be
identified in perpendicular sections. This in turn requires large
biopsy forceps (e.g. radial jaw 4 or equivalent), taken through
standard endoscopy biopsy channels, and laboratory techni-
cians skilled in embedding, cutting and staining these biopsies.
6.2. Histological scoring systems
Many indices to assess disease activity in UC have been
described since the 1950s, though none are fully validated
(Table 1).18,26,27,49–52,54–56,60–67 This systematic review and
that of Mosli et al., has identified 22 histological scoring
systems for UC.44 The first described was that by Truelove
and Richards in 1956 in a study of 111 serial biopsy specimens
from 42 patients with UC.56
The most widely used histological indices of disease
activity in UC are the Riley Index (1991)18 and the Geboes
Index (2000).50 The Riley Index evaluates six features (acute
inflammatory infiltrate, crypt abscesses, mucin depletion,
epithelial integrity, chronic inflammatory infiltrate, and
crypt architectural abnormalities), each of which is graded
subjectively on a 4 point scale, and given equal weight.18
The Geboes Index includes five features (architectural change,
lamina propria neutrophils and eosinophils, neutrophils in
epithelium, crypt destruction, and erosion or ulceration). This
is the best validated (interobserver variability κ 0.59–0.70,
indicating moderate to good agreement between 3 specialist
pathologists).50 It also predicts relapse in patients with clin-
ically and endoscopically quiescent UC over 12 months.20,24
However, there is no grading for basal plasmacytosis in any
system and this appears to be a deficiency.
Scoring systems for CD are limited by discontinuous disease
so they require targeted biopsies, while transmural inflam-
mation can only be evaluated in resections, so it is not ame-
nable to a biopsy driven scoring system. Validation remainschallenging.57,68,69 The Colonic and Ileal Global Histologic
Disease Activity Score (CGHAS or IGHAS)57,70,71 incorporates
epithelial damage, architectural changes, mononuclear or poly-
morphonuclear cells in the lamina propria and epithelium,
presence of erosions/ulcers and granulomata, as well as the
number of segmental biopsy specimens affected.57 It is not
validated so its role remains undefined.
6.2.1. Appraisal
Standardization and optimization of the collection and
processing of biopsy specimens in IBD is imperative for accu-
rate assessment of histopathological activity or remission.
Histological scoring systems in IBD vary in histological
features, terminology and classification of severity. None of
the scoring systems are fully validated, though several UC in-
dices are partially validated.
As described, the Riley Index is difficult to reproduce,
because criteria for separating grades are not provided, the
best being illustrations of mean grades of acute inflamma-
tion and mucin depletion. Any subsequent use of this index
therefore requires specific modifications. Although statistical
validation is unlikely to give equal weight to six measures, the
score did predict the likelihood of relapse in the following
year. The Geboes Index is also subjective for chronic inflam-
mation (grade 1), and eosinophils and neutrophils in the lamina
propria (grade 2), but acute inflammation in the crypts through
ulceration is well defined. The Geboes Index has all of the pre-
requisites to grade all aspects of inflammation, as well as archi-
tecture and we believe that it should be the basis for an agreed
scoring system to define histological remission and disease
activity. Nevertheless, modification of the existing Geboes Index
to include of basal plasmacytosis, shown independently to pre-
dict clinical relapse in UC (see below), appears appropriate.
A scoring system is essential to measure improvement in
an individual, or to relate histopathology to clinical outcomes
for patients. Assessmentwill require further regression analysis
of specific histological features, as well as the relationship with
an endoscopic scoring system such as the Mayo Clinic index or
ulcerative colitis endoscopic index of severity (UCEIS).72
7. Current trials and evidence for histological
remission as an endpoint
7.1. Histological healing versus endoscopic mucosal
healing
Histological healing is distinct from endoscopic mucosal
healing in UC. Studies have demonstrated that microscopic
inflammation persists in 16–100% of cases of endoscopically
quiescent disease (Table 2).18,19,21,24,49,51,55,56,63,65,66,73–76
Histopathology is more likely to reflect residual inflamma-
tion than endoscopy, particularly in the presence of ‘minimal’
or ‘mild’ disease identified endoscopically.19,76 Better con-
cordance between endoscopy and histopathology is evident
during the presence of inactive or severely active disease, but
between these extremes there was a full range of histological
grades, and therefore a poor correlation between the two.76
Persistent histological inflammation also occurs in 25–37% of
patients with clinical and endoscopically quiescent CD,48,77
although inflammation beyond the reaches of the endoscope
and patchy inflammation make interpretation more difficult.
Table 1 Histological Scoring Systems in Inflammatory Bowel Disease.
IBD Author, year Key features of score Comments
Ulcerative
colitis
Truelove & Richards,
(1956)56
3 grade scale: 1) no inflammation 2) mild to
moderate inflammation 3) severe inflammation
Partially validated.
Extensive use in clinical trials
and RCT's.
Matts et al. (1961)63 5 grade scale: 1) normal to 5) ulceration, erosion,
or necrosis of the mucosa, with cellular infiltration
of some or all of its layers
No validated.
Extensive use in clinical trials
and RCT's.
Watts et al. (1966)65 4 grade scale: 0) normal to 3) severe inflammatory
change
Not validated
Korelitz et al. (1976)54 Mucosal cell counting in addition to histologic
features
Not validated
Cell counting labor intensive
Powell-Tuck et al. (1982)55 3 grade scale: 1) no inflammation 2) mild
inflammation 3) moderate/severe inflammation
Not validated
Keren et al. (1984)62 Dichotomized: active versus inactive inflammation Not validated
Friedman et al. (1986)61 4 grade scale: 0) normal 1) lamina propria
inflammation 2) crypt injury 3) ulceration
Not validated.
Subsequent use in clinical trials.
Gomes et al. (1986)51 5 grade scale 0) normal, to 4) severe
inflammation and active ulceration
Not validated
Subsequent use in clinical trials
Saverymutti et al. (1986)60 4 histological features: 1) enterocyte damage
2) crypt abnormalities 3) lamina propria involvement
4) acute inflammatory infiltrate in the lamina
propria. Each graded from 0) normal to 3) severe.
Not validated
Extensive clinical trials
and RCT's.
Floren et al. (1987)49 5 grade scale: 0) normal, to 5) severe
inflammation and ulceration
Not validated.
Extensive clinical trials and RCT's.
Riley et al. (1991)18 6 histological features assessed;
each graded on a 4 point scale
Partially validated.
Prognosticates time to relapse.
Extensive clinical trials and RCTs.
Hanauer et al. (1993)52 4 grade scale: 0) normal colonic mucosa to 3) high
grade active inflammatory bowel disease (combines
histologic and endoscopic appearances)
Not validated.
Central reference pathologist
Sandborn et al. (1993)64 4 grade scale: 0) inactive chronic colitis to
3) severely active chronic colitis
Not validated.
Geboes et al. (2000)50 7 histological features graded
Scoring from 0 to 5.4
Partially validated.
Subsequent clinical studies.
Harpaz Score
Fiel et al. (2003)67
Harpaz Score: 4 grade scale: 0) no cryptitis,
1) cryptitis b50% crypts, 2) cryptitis N50%
crypts 4) ulcerations or erosions.
Partially validated.
Subsequent clinical studies.
Rutter et al. (2004)27 5 grade scale: 0) normal to 4) severe active
inflammation
Not validated.
Rubin et al. (2007)26 6 grade scale: 0) normal to 5) crypt abscesses
in N50% of crypts or erosion/ulceration
Not validated. Case control
prospective grading by two
pathologists to validate internally
Baars et al. (2012)66 4 grade scale: 0) no active disease to 4) severe
inflammation (numerous crypt abscesses)
Not validated.
Crohn's
Disease
D'Haens et al. (1998)57 16 point grading system
8 histological and distribution features
Subsequently called the CGHAS
and IGHAS in clinical trials^
Nicholls et al. (1994)69 4 grades: 1) worse 2) no change,
3) improvement, 4) resolution of inflammation
Subjective. Not validated.
Breese et al. (1995)68 5 histological features (ulceration, acute and
chronic inflammation, crypt distortion, goblet
cell depletion and villous atrophy). 4 grades:
0) normal to 3) severely inflamed.
Not validated.
Baars et al. (2012)66 4 grade scale: 0) no active disease to 4) severe
inflammation (numerous crypt abscesses)
Not validated.
Key: RCT, randomized controlled trial; CGHAS, Colonic Global Histologic Disease Activity Score; IGHAS, Ileal Global Histologic Disease Activity
Score.
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Table 2 Endoscopic mucosal assessment versus histological assessment of disease activity.
IBD Author, year Patient
number
(n)
Endoscopic versus Histologic Findings
Ulcerative
colitis
Truelove &Richards (1956)56 111 Normal sigmoidoscopy: 6/16 (38%) mild/mod inflammation
Dick and Grayson (1961)73 48 Normal sigmoidoscopy: 6/19 (32%) acute or chronic inflammatory infiltrate
Watts et al. (1966)65 105 Normal sigmoidoscopy: 31/60 (52%) mild or severe inflammation
Powell-Tuck (1982)55 72 Normal sigmoidoscopy: 3/11 (27%) mild or mod-severe inflammation
Gomes (1986)51 28 Sigmoidoscopic score well correlated with histological score: (R 0.61 p b 0.001)
Floren et al. (1987)49 33 In 57 endoscopically normal colonic segments assessed: 100% ‘slight’
inflammation, 16% intermediate/severe inflammation
Riley et al. (1991)18 82 Normal mucosa endoscopic appearance or erythema: 100% chronic
inflammatory infiltrate, 58% crypt irregularities, 28% acute
inflammatory infiltrate.
Bitton et al. (2001)21 74 Normal endoscopic appearance: basal plasmacytosis predictive of
relapse (HR 4.5 CI 1.7–11.9 p = 0.003)
Thomas et al. (2009)74 91 Endoscopic remission as per Baron score121: agreement between
histologic and endoscopic assessment in 58%
Bessissow et al. (2012)24 75 Normal endoscopic appearance: Geboes score ≥3.1 in 40%, basal
plasmacytosis in 21%
Baars et al. (2012)66 98 Endoscopic remission as per Mayo score: 31% at least mild histological
inflammation
Lemmens et al. (2013)76 131 Significant correlation between Mayo endoscopic subscore and histology
(Kendall's T = 0.482 p b 0.001), highest for inactive or severely active disease
Rosenberg et al. (2013)19 103 Colonic segment with Mayo endoscopy subscore 0: 6% histological inflammation
Molander et al. (2013)48 62 Patients in 'deep remission' (Physician global assessment and
Mayo Clinic endoscopic subscore): 7% histological inflammation
Crohn's
disease
Korelitz et al. (1984)77 38 37% histological inflammation in presence of endoscopic disease quiescence
Molander et al. (2013)48 183 Patients in ‘deep remission’ (according to Physician global assessment
and Simple Endoscopic Score for Crohn's Disease): 25% histological
inflammation
Baars et al. (2012)66 46 Endoscopic remission as per Mayo score: 40% histologic inflammation
1587Histological remission in IBDNevertheless endoscopic assessment so far has no role in pre-
dicting relapse in CD.
7.2. Prognostic value of histology in IBD
Early studies in UC by Wright and Truelove proposed that
persistent histologic inflammation may be a better predictor
of future clinical relapse than endoscopic appearances alone.23
This has been borne out in subsequent studies for predicting
relapse in patients with UC that is evaluated as clinically and
endoscopically quiescent (Table 3).
Riley et al. showed that active histological inflammation
predicted clinical relapse during 12 months of follow-up,
whereas endoscopic features (normal mucosa or erythema
at study entry) did not.18 Relapse rates were higher in the
presence of an acute inflammatory infiltrate (52% vs 25% p =
0.02), crypts abscesses (78% vs 27% p b 0.0005), mucin de-
pletion (56% vs 26% p b 0.02), and any breach in surface ep-
ithelium (75% vs 31% p = 0.01). Bitton et al. showed that basal
plasmacytosis was the principal histological predictor of relapse,
independent of maintenance therapy, among 74 patients with
clinically and endoscopically quiescent UC.21 Azad et al. found
that increased numbers of lamina propria neutrophils and
eosinophils are associated with a higher risk of relapse over
12 months in patients with quiescent UC,20 while Bessissow et
al. found that a Geboes score of ≥3.1 (any crypt abscesses —but in addition an increase in lamina propria neutrophils (2B-1)
or eosinophils (2A-1)) predicts clinical relapse (Mayo Clinic
score changing from 0 to ≥3).24 This latter study also con-
firmed that basal plasmacytosis (not part of the Geboes Index)
was associated with a higher risk of relapse (p = 0.007).24
Resolution of histological inflammation in UC has also been
associated with a higher likelihood of remaining symptom-free
at 12 months after a course of corticosteroids78 and a reduction
in hospitalization or colectomy rates,25,26,79,80 in one case over
the course of 2.5 years.80 Consistent with this observation, a
higher mean inflammation score during a colonoscopic screen-
ing program for UC was a significant predictor for colectomy.25
Furthermore, histological remission has been shown to corre-
late with a reduction in colorectal cancer risk in UC.22,27
The prognostic value of histology has only been assessed in a
single study in CD, which found thatmucosal inflammation was
not associated with more frequent clinical relapse, stricture
formation, or surgery,66 although patchiness of inflammation
makes this difficult to interpret.
7.3. Therapeutic trials and histological remission
Few therapeutic trials have incorporated histological assess-
ment of activity in IBD, most being concerned with histology
for diagnostic purposes, and even fewer report histological
remission (Table 4).29,45,46,48,53,81–93
Table 3 Prognostic value of histopathology in IBD.
IBD type Author, date Patient number/
follow-up period
Scoring system Disease-related outcome and
histological predictor
Ulcerative colitis Wright and
Truelove
(1966)23
n = 77
12 months
Truelove and
Richards Score
(see Table 1)
Clinical relapse rate
Predicted by histological disease activity.
Riley et al.
(1991)18
n = 82
12 months
Riley Score
(see Table 1)
Clinical relapse rate
33% clinical relapse. Predicted by acute
inflammation 52 vs. 25% (p 0.02); Crypt
abscesses: 78 vs. 27% (p b 0.005); Mucin
depletion: 56 vs. 26% (p b 0.02); Surface
epithelium breach: 75 vs. 31% (p = 0.1).
Bitton et al.
(2001)21
n = 74
12 months
Normal or abnormal.
If abnormal: active
colitis, chronic colitis,
Paneth cell metaplasia,
basal lymphoid
aggregates and
plasmacytosis.
Clinical and endoscopic relapse rate
36.5% relapse rate. Predicted by basal
plasmacytosis (HR 4.3 1.7–11.0, p = 0.003).
Azad et al.
(2011)20
n = 26
12 months
Geboes Score
(see Table 1)
Clinical relapse rate
57.7% clinical relapse. Predicted by
eosinophils & neutrophils in lamina propria
(p = 0.01).
Hefti et al.
(2009)25
n = 561
21.4 years
Harpaz Index
(see Table 1)
Colectomy rate
17.3% colectomy rate; 26% of these for
dysplasia. Mean mucosal inflammation
predictive of colectomy overall (p b 0.001).
Rubin et al.
(2007)26
n = 106 Rubin et al. Score
(see Table 1)
Colectomy and hospitalization rates Correlated
with increased histological inflammation
(HR 1.9, 95% CI 1.02–3.51, p 0.042;
HR 1.52 95% CI 0.9–2.61, p 0.123 respectively;
relative to a 1 point increase in inflammation).
Burger et al.
(2011)80
n = 91
29 months
Truelove and
Richards Score
(see Table 1)
Colectomy and hospitalization rates
Predicted by histologic activity.
Bessissow
et al. (2012)24
n = 75
12 months
Geboes Score
(see Table 1)
Basal
plasmacytosis
Clinical relapse rate
20% relapse rate. Predicted by basal
plasmacytosis (p = 0.007), and Geboes
Score ≥3.1 (p = 0.007)
Gupta et al.
(2007)22
n = 418
2168 patients years
Harpaz Score
(see Table 1)
Colorectal dysplasia and neoplasia
3.6% advanced neoplasia. Inflammation over
follow-up period (IS-mean) correlated with
risk of neoplasia (HR 3.0, 95% CI 1.4–6.3)
Rutter et al.
(2004)27
n = 68
(136 controls
with colorectal
neoplasia)
Rutter et al. score
(see Table 1)
Colorectal neoplasia
68 UC patients with colorectal neoplasia
matched to controls.
Histologic inflammation correlates with risk
of colorectal neoplasia (OR 5.1 p b 0.001)
Baars et al.
(2012)66
n = 98
6.8 years
Baars Score
(See Table 1)
Relapse, surgery, mortality
No evidence of increased relapse rates,
surgery, or mortality in patients with
histological inflammation and normal
endoscopic appearances (p N 0.05)
Crohn's
disease
Baars et al.
(2012)66
n = 46
6.8 years
Baars Score
(see Table 1)
Relapse, surgery, mortality
No evidence of increased relapse rates,
surgery, or mortality in patients with
histological inflammation and normal
endoscopic appearances (p N 0.05)
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1589Histological remission in IBDHistological response to therapy has been reported in
multiple trials in UC, the first of which was in the 1950s in
patients treated with steroids (Table 4).29,45,53,83,85,90–92
Histological improvement has been reported after oral
budesonide therapy (47% of patients with UC in a review
including three randomized controlled trials)92 and also
after aminosalicylates, occasionally achieving histological
remission.46,82,84,86,88,89 In a Cochrane review, rectal 5-ASA
was superior to placebo for inducing histologic improvement
(OR 7.69 p b 0.0001) and remission (OR 6.28 p b 0.0001) in
the 6/38 trials using histopathology as a secondary or post-hoc
endpoint.46 In a comparison between single and divided doses
of oral 5-ASA (3 g daily) in 380 patients with active UC,
histological remission was achieved in 35% and 41% respec-
tively.84 Remarkably few studies have assessed histological
response to immunomodulator or biological therapy.48,81,87 In
one study of 62 patients treated with infliximab for UC,
clinical and endoscopic remission was achieved in 62%, of
whom 93% also demonstrated histological healing.48 As a twist
in the tail for clinical studies of UC, independent evidence of
histological activity at trial entry was a pre-specified require-
ment for the analysis in two recent trials of mild-moderate UC,
to ensure that the population studied had objective evidence
of disease activity at the time of recruitment: up to 20%
with apparent endoscopic activity did not meet this simple
criterion.94,95
Even fewer studies have assessed the histological re-
sponse to therapy in CD, but most have involved biological
therapy.11,48,71,96–100 In a study of 30 steroid-refractory
patients with CD, D'Haens et al. showed that infliximab
induced improvement in the mucosal inflammatory infiltrate,
although cytoarchitectural changes persisted after 4 weeks of
therapy.70 This result therefore mimics findings in ulcerative
colitis; in neither disease are architectural changes expected
to regress with resolution of the acute inflammation. Histo-
logic improvement after 10 weeks of therapy with infliximab
was also a feature of the pivotal ACCENT1 Trial.71,101 Some
studies have also demonstrated histological improvement
after enteral feeding in patients with CD.102–1047.3.1. Appraisal
Collectively this literature implies that histological remission
offers the potential for predicting the risk of disease-related
complications in UCbeyondendoscopicmucosal healing, though
data are scarce in CD. Despite the variable reporting of
histopathology in therapeutic trials, there is evidence to suggest
that histological remission may be achieved, and may be
associated with better patient-related outcomes after treat-
ment for UC. Both Riley and Geboes indices have been shown
to predict clinical relapse, though neither scoring system
incorporates basal plasmacytosis, which has shown to be an
independent predictor of relapse in UC. The data are less
strong in CD, although this may be attributable to the fact that
histology has been less frequently incorporated into trial de-
sign as a treatment endpoint. Yet, endoscopic mucosal healing
in CD, analogous to UC, has been shown to be associatedwith a
reduced likelihood of requiring surgery or hospitalization in an
endoscopic sub-study of maintenance infliximab.13 Biopsies
were not taken to allow histological evaluation in this study,
despite the fact that a previous study had shown that histo-
logical healing occurs following therapy.70Ideally remission should include clinical, endoscopic and
histological components. Concordance between these three
components might be termed ‘complete remission’. This will
require a paradigm shift in clinical trials and practice, but
pathologists are rarely consulted in the design of trials.
However, since the FDA are moving toward documentation
of both active histological disease at trial inclusion, as well
as tissue evidence of remission, especially for trials of bio-
logical therapy, this may change.8. Limitations of histological assessment in IBD
Assessment of histological healing in IBD has several limita-
tions. The relative lack of validation or standardization of
histological reporting, scoring, and definition of remission are
current notable limitations for using histological healing as a
therapeutic endpoint,40 even though in well orientated biop-
sies, it is actually fairly easy to determine whether neutrophils
or deep plasma cells are present. Furthermore,mucosal biopsy
necessitates invasive endoscopic investigation, which risks
complications and increases costs and time for patients,
clinicians and pathologists alike. However, this is a “Catch-22”
situation, because unless these issues are either confirmed or
refuted, the questions will remain unanswered. In this case we
will continue to titrate treatment of patients against symptoms
or endoscopic appearance. The demonstration of mucosal
healing by endoscopy, itself an indication of healing, requires
some form of endoscopy, which although “invasive”, is minimal
compared tomany other procedures. It is logical to argue that if
an endoscopic endpoint is adopted, then this should include
biopsies for histopathology.
While it is possible that acute inflammatory mediators or
biomarkers may be detectable in stools, these are at best an
aid. It is currently difficult to extend this to stool tests that
might reasonably substitute for biopsy to estimate the quantity
or depth of mucosal chronic inflammation, or eosinophils.
Discontinuous inflammation, characteristic of CD, introduces
sampling error for histological assessment. In UC, disease
duration and treatment may alter the distribution and nature
of microscopic changes.40,41,105–110 Transmural inflammation
in CD may also mean that histologic mucosal healing does not
represent quiescent disease, since deeper inflammation,
although invariably in the form of lymphoid hyperplasia, and
therefore reflecting chronic inflammation rather than acute
inflammation, may persist.28,41 Myenteric plexitis, for exam-
ple, which is relatively uncommon but also a variant of chronic
inflammation, predicts post-operative relapse in CD, and
obviously is also not amenable to biopsy.111 In both UC and
CD, it is pertinent to takemultiple, quality, segmental biopsies,
targeting areas of visible endoscopic inflammation, in order to
reduce sampling error for histological assessment. Correct
cutting and orientation of biopsies by pathologists is extremely
important for assessing the depth of inflammation or basal
plasmacytosis.9. Summary and future directions
The concept of histological healing as a therapeutic endpoint
is based on the premise that persistent inflammation in IBD
leads to earlier relapse, progressive damage and cumulative
Table 4 Histologic remission and therapy in IBD.
IBD type Therapy Author, date Patient number Key features Outcomes
Ulcerative
colitis
Corticosteroids Truelove et
al. (1958)29
n = 40
Distal UC
Rectal hydrocortisone
1 week therapy
Truelove and
Richards score
55% shift to a mild grading.
No histological ‘normalization’.
Sommers et
al. (1975)
n = 215 Prednisolone
(+/−mercaptopurine)
for 2 weeks
Mucosal cell counts:
decreased neutrophils and
plasma cells.
Ruddell et
al. (1980)90
n = 30
Distal UC
Hydrocortisone enema
vs. foam
2 weeks therapy
Significant improvement in
active inflammation in
enema group.
Lee et al.
(1996)85
n = 295
Distal UC
Randomized trial
Prednisolone foam
enema vs. mesalazine
foam enema assessed
at 4 weeks
Histologic remission in
27% mesalazine vs 21%
steroid group.
Hanauer et
al. (1998)53
n = 233
Distal UC
Budesonide enema (dose
finding) vs. placebo.
Modified Truelove and
Richards score
Overall histologic improvement
in budesonide groups (2 mg/
100 mL and 8 mg/100 mL).
Gross et al.
(2006)83
n = 449
Distal UC
Budesonide foam vs. enema
Riley scoring18
Histological improvement
in 51% foam enema and 57%
liquid enema.
Sherlock et
al. (2010)92
3 studies Cochrane review: oral
budesonide therapy
46.9% histological remission
Hartmann et
al. (2010)45
n = 237
Left-sided
UC
Mesalazine enema vs.
budesonide enema
assessed at 4 weeks
Non-significantly higher
histologic remission with
mesalazine (48.6%) vs
budesonide (43%)
(p = 0.145)
Salicylates Rao et al.
(1989)89
n = 37
Distal UC
Olsalazine (2 g/day) vs.
sulfasalazine (3 g/day)
assessed at 4 weeks
Histologic improvement in
both groups similar (44% and
46% respectively, p = NS)
Green et al.
(2002)82
n = 57
Active UC,
variable
distribution
Balsalazide (6.75 g/day)
vs. sulfasalazine (3 g/day)
(+steroids if needed)
assessed at 12 weeks
Similar histological
improvement in both groups
Mansfield et
al. (2002)86
n = 50
Active UC
variable
distribution
Balsalazide (6.75 g/day)
vs. sulfasalazine (3 g/day)
assessed at 12 weeks
Histological improvement
overall. 34% no histological
inflammation overall.
Prantera et
al. (2005)88
n = 79
Active
Left-sided UC
Slow release mesalazine
vs. topical 5ASA
Floren score49
Histological remission in
15% of oral and 8% of enema
treated groups.
Kruis et al.
(2009)84
n = 380
Active UC Variable
distribution
Mesalazine granules
3 g/day in single or thrice
daily dosing
Histological remission in
35% of single dosing and 41%
of thrice daily dosing groups
Marshall et
al. (2010)46
Cochrane Review
6 trials
(of 38 included)
Rectal 5ASA for
induction of remission
in UC
Superior to placebo in inducing
histologic remission
(OR 6.28, p b 0.0001)
Immunomodulator Paoluzi et
al. (2002)87
n = 32
Active
refractory UC
Azathioprine or
methotrexate for 6 months
Truelove and
Richards score56
78% histological remission at
6 months
Biological agents Chey et al.
(2007)81
n = 16
Active
refractory UC
Infliximab
Single infusion (5 mg/kg),
6/16 patients had a 2nd
infusion at 5 months
Significant improvement
from baseline in histologic
score (p b 0.001)
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Table 4 (continued)
IBD type Therapy Author, date Patient number Key features Outcomes
Molander et
al. (2013)48
n = 62 TNF-alpha antagonists
(infliximab and
adalimumab)
for N11 months
UC patients in ‘deep remission’
(clinical and endoscopic), 93%
histologically inactive disease
Crohn's
disease
Corticosteroids Mantzanis et
al. (2009)100
n = 77
Steroid
dependent
inflammatory
colonic or
ileocolonic CD
Budesonide vs
azathioprine
1 year therapy
D'Haens Score57
No significant improvement
in histology on budesonide
Baars et al.
(2010)96
n = 30
CD colonic
distribution
Oral prednisolone
20 mg for 2 weeks
Geboes Score50
Decrease in histological activity
compare with placebo, no
significant differences in
severity of inflammation
Immunomodulator D'Haens et
al. (1997)97
n = 19
Recurrent
neoterminal ileal
disease
Azathioprine for
6 months
Microscopic inflammatory
infiltrate resolved only in
those with macroscopic
healing at endoscopy (70%).
D'Haens et
al. (1999)98
n = 20
Ileocolonic
distribution
Azathioprine for
9 months
D'Haens Score57
Colonic endoscopic healing:
decreased histological score.
Ileal endoscopic healing,
decreased histological score.
Mantzaris et
al. (2009)100
n = 77
Steroid
dependent
inflammatory
colonic or
ileocolonic CD
Budesonide vs
azathioprine,
1 year of therapy
D'Haens Score57
Endoscopic mucosal healing
in 83% of patients, significant
reduction in histologic scores
(mainly inflammatory) but
not remission
Kozarek et
al. (1989)99
n = 14
Refractory
disease
Methotrexate 25 mg
IM weekly
12 weeks
28.5% patients ‘normal’
histology at 12 weeks
Biological agents D'Haens et
al. (1999)70
n = 30
Steroid
refractory
ileocolonic
Infliximab
Single infusion of
5–20 mg/kg vs.
placebo assessed at
4 weeks
Improvement in histological
inflammatory infiltrate but
persistent cytoarchitectural
changes
Baert et al.
(1999)93
n = 13
Steroid
refractory
ileocolonic
Infliximab
Single infusion
5–20 mg/kg vs. placebo
assessed at 4 weeks
Reduced histological activity
Geboes
et al. (2005)71
n = 48 Infliximab 5–10 mg/kg
(ACCENT1 Study
follow-up)101
D'Haens Scoring57
Improved colonic histological
disease activity at week 10.
Molander
et al. (2013)48
n = 183 Tumor necrosis
factor-alpha antagonists
(infliximab and
adalimumab) N11 months
43% endoscopic remission,
75% of these patients in
histological remission.
1591Histological remission in IBDdisability. This confers an increased risk of hospitalization,
colectomy, and colorectal cancer.112,113 It is conceived that
suppression of inflammation early in the course of disease may
prevent disease-related complications and prolong remission,
akin to other chronic inflammatory conditions such as
rheumatoid arthritis.114,115
Histological remission in either UC or CD is currently not
considered a clinical target; indeed, even endoscopic remissionmay not be sought. However, histological remission is a poten-
tial target quite distinct from endoscopic mucosal healing,
and, data suggest that it is likely to be of greater value for
improving patient outcomes and reducing disease-related
complications. There is a need for a standardized histological
scoring system for IBD, which must be validated, reliable and
reproducible. Modification of the existing Geboes Index to in-
corporate basal plasmacytosis would be rational and achievable
Figure 1 Biopsies taken from two patients in clinical and
endoscopic remission (Mayo score of 0 or 1) following therapy for
ulcerative colitis. A There is residual architectural distortion but a
dearth of inflammatory cells in the lamina propria. Residual cells
are all mononuclear with no neutrophils or eosinophils and scant
plasma cells. B,C. Biopsy from a second patient following therapy
in which there is architectural distortion but a dense lamina
propria infiltrate. C. Detail of B in which, while there are no
neutrophils, and therefore no “activity”, but there are numerous
eosinophils and plasma cells in the lamina propria.
1592 R.V. Bryant et al.in the process of further work on validation. It remains necessary
to confirm theprognostic value of histologic remission beyond, or
independent of, that associatedwith endoscopicmucosal healing
alone, through clinical trials. While histological healing occurs in
CD, the benefits of achieving histological remission in CD remain
unclear. Incorporation of histological remission into routine
clinical practice is a transition that will require a paradigm
shift in thinking among clinicians.
Initially histological healing may seem too difficult a
treatment target, however, the implied changes in the man-
agement algorithm require common sense and not extreme
measures (such as putting patients on biologicals to get ridof the last crypt abscess). Rather, in patients in clinical re-
mission, assessment of histology can assist with the clinical
question being asked: is it reasonable to reduce therapy?
Compare the two biopsies shown in Fig. 1, both from patients
in clinical and endoscopic remission (Mayo Clinic score of 0 or
1) following therapy. Which is the most likely to relapse first?
Incorporation of histology into clinical decision-making is like-
ly to be far more applicable to patients either in remission or
with mild activity, in whom 5-aminosalicylic agents, or possibly
non-systemic steroids (budesonide) are being used. This is
because such patients are the easiest to maintain in that state
without reducing the dose. On the other hand, the appear-
ances of endoscopic remission in these patients may be falsely
reassuring and lead to a potentially inappropriate reduction
in treatment. Histopathology would provide additional infor-
mation that predicts an increased rate of relapse (mucosal
neutrophils, basal plamacytosis), providing a reason not to
reduce therapy further, until these changes have also regressed.
This simply reflects common sense and may not be so far from
specialist practice today. Conversely this policy may be less
easy to implement in patients on immunosuppressives, in-
cluding biologicals, in whom the immediate objective may be
simple symptom reduction to the point that hospitalization is
not required. This is because histopathological activity would
imply dose escalation in (potentially) asymptomatic patients,
which would raise greater concerns about risk versus benefit.
These differing clinical scenarios need to be kept separate
from each other when examining treatment to targets.
Clinical trials will be required to determine whether
patients should be “titrated” against lack of histological
features that predict risk of relapse, as well as established
clinical and endoscopic features, in order to maintain re-
mission. One arm would inevitably need to explore whether
reappearance of these histological features should, by them-
selves, result in some form of increase in therapy.
Future histological assessment in IBD must validate the
role of histopathology in the standard management of
patients, both in clinical trials and practice, especially
those in apparent clinical remission. Looking beyond con-
ventional staining, mucosal whole-genome analysis suggests
that there may be a transcriptional signature in patients
with quiescent UC, possibly associated with defective healing
and failure to restore mucosa-associated microbiota.116,117
Since mucosal gene signatures, their translation, epigenetic
modification, post translational modification and their proteo-
mic expression may predict response to biological therapy in
UC.118 The latter are often detectable by immunohistochemis-
try, and are therefore one future direction for predicting
disease outcomes, or response to therapy. Histological assess-
ment in IBD may also involve new technology. Confocal laser
endomicroscopy, especially for UC, has the potential to provide
real-time microscopic assessment (‘endopathology’), that may
represent a new way of evaluating histologic healing that may
predict relapse.16,119,120
That histological remission as a target for therapy in IBD
is currently far removed from traditional thinking and the
standard management mindset of academic gastroenterolo-
gists, despite supporting evidence, is reflected in current trial
design. This can, and we argue, should, change. Surprisingly, it
may be the FDA, who increasingly requires independent evi-
dence of activity for recruitment to clinical trials, or histopath-
ological remission as part of the endpoint of clinical trials, who
1593Histological remission in IBDwill be the catalyst for changing themindset of clinicians. This is
likely to be in the long-term interests of changing the course of
IBD, toward ‘complete’ remission as a target for treatment.Conflict of interest
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